Generation Bio Co (GBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Generation Bio Co (GBIO) has a cash flow conversion efficiency ratio of -1.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.68 Million) by net assets ($50.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Generation Bio Co - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Generation Bio Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GBIO liabilities breakdown for a breakdown of total debt and financial obligations.
Generation Bio Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Generation Bio Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beaconsmind AG
PA:MLBMD
|
-1.608x |
|
Wooyang Co. Ltd
KQ:103840
|
0.073x |
|
NBI Bearings Europe S.A.
MC:NBI
|
0.043x |
|
Arzum Elektrikli Ev Aletleri Sanayi ve Ticaret AS
IS:ARZUM
|
7.089x |
|
George Kent (Malaysia) Bhd
KLSE:3204
|
0.037x |
|
GiG Software PLC
ST:GIG-SDB
|
0.010x |
|
Sunndal Sparebank
OL:SUNSB
|
N/A |
|
Acrinova AB
ST:ACRI-A
|
0.025x |
Annual Cash Flow Conversion Efficiency for Generation Bio Co (2018–2024)
The table below shows the annual cash flow conversion efficiency of Generation Bio Co from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see GBIO stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $86.20 Million | $-88.56 Million | -1.027x | -295.65% |
| 2023-12-31 | $203.13 Million | $-52.74 Million | -0.260x | +28.40% |
| 2022-12-31 | $282.49 Million | $-102.45 Million | -0.363x | -50.77% |
| 2021-12-31 | $381.75 Million | $-91.82 Million | -0.241x | +8.09% |
| 2020-12-31 | $268.01 Million | $-70.14 Million | -0.262x | -163.95% |
| 2019-12-31 | $-98.59 Million | $-40.35 Million | 0.409x | -39.47% |
| 2018-12-31 | $-41.59 Million | $-28.12 Million | 0.676x | -- |
About Generation Bio Co
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise me… Read more